Causes of screen failures (February 2011 through April 2017), N = 561
| Cause . | n/N . | % . |
|---|---|---|
| Failed eligibility criteria | 233/561 | 41 |
| Multiple comorbidity | 135/233 | |
| Thrombocytopenia | 32/233 | |
| Neutropenia | 3/233 | |
| Pancytopenia | 15/233 | |
| Relapsed or graft failure | 29/233 | |
| Secondary malignancy | 5/233 | |
| Other | 14/233 | |
| Patient was not interested | 129/561 | 23 |
| Physician was not interested (some received AZA off-study) | 84/561 | 15 |
| Detectable minimal residual disease after transplant (received AZA off-study) | 26/561 | 5 |
| No clinical trial benefit | 28/561 | 5 |
| Outside physician refused | 10/561 | 2 |
| On competing IND study | 10/561 | 2 |
| Cause . | n/N . | % . |
|---|---|---|
| Failed eligibility criteria | 233/561 | 41 |
| Multiple comorbidity | 135/233 | |
| Thrombocytopenia | 32/233 | |
| Neutropenia | 3/233 | |
| Pancytopenia | 15/233 | |
| Relapsed or graft failure | 29/233 | |
| Secondary malignancy | 5/233 | |
| Other | 14/233 | |
| Patient was not interested | 129/561 | 23 |
| Physician was not interested (some received AZA off-study) | 84/561 | 15 |
| Detectable minimal residual disease after transplant (received AZA off-study) | 26/561 | 5 |
| No clinical trial benefit | 28/561 | 5 |
| Outside physician refused | 10/561 | 2 |
| On competing IND study | 10/561 | 2 |
AZA, azacitidine; IND, investigational new drug.